Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related mortality worldwide, claiming over 700,000 lives annually. The liver's central role in blood filtration and metabolism makes it an attractive target for drug delivery, with lipid nanoparticles (LNPs) showing particular promise due to their natural hepatic tropism. However, LNP efficacy becomes compromised in HCC environments due to inadequate understanding of liver physiology under cancerous

protective antibodies create significant challenges for vaccination programs by interfering with vaccine-induced immune responses, thereby reducing vaccine effectiveness. This interference has been well-documented with whole inactivated virus (WIV) vaccines against SwIAV, creating an urgent need for innovative vaccination strategies that can overcome MDA interference while maintaining protective efficacy. The significance of this research extends beyond swine health, as Sw

This research falls under the broader scientific discipline of molecular biology and cancer therapeutics, specifically within RNA-guided genome editing and precision oncology. CRISPR-Cas13d systems represent a powerful class of RNA-targeting tools that can precisely edit target transcripts with minimal off-target effects. However, their clinical development faces significant challenges. One of these is the limited biostability of conventional linear guide RNAs (lgRNAs) suscep

Max-Planck-Institut für Kohlenforschung: New study reveals stereochemistry of lipid nanoparticles critically influences safety and efficacy in mRNA delivery Nagoya University: Japanese researchers engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively using cyclic disulfide modifications University of Pennsylvania: Study unlocks safer RNA therapies by reducing harmful inflammation caused by lipid nanoparticles using biodegradable lipids